Final draft guidance from the UK’s National Institute for Health and Care Excellence (NICE) recommends the use of elacestrant, the first tailored treatment for locally advanced and metastatic breast cancer with mutations in the ESR1 gene. Specifically, the drug will be available on the NHS to treat post-menopausal women, and men, with oestrogen receptor (ER)-positive […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!